美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Leverage Shares 2X Long ENTG Daily ETF

6.09

+0.03020.50%

盤後：5.98-0.1111-1.83%19:30 EDT

成交量：1,809

成交額：1.11萬

市值：15.22萬

市盈率：- -

高：6.29

開：6.20

低：5.90

收：6.06

52周最高：14.51

52周最低：4.60

股本：2.50萬

流通股本：2.50萬

量比：0.90

換手率：7.24%

股息：- -

股息率：- -

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

更多創新藥有望納入醫保報銷

創新生物製劑落地中國！雙適應症惠及重度哮喘與鼻息肉患者

泰適卓®雙適應症在華上市，為重度哮喘、慢性鼻竇炎伴鼻息肉患者提供生物製劑創新治療選擇

康諾亞-B(02162)：CM512(TSLP x IL-13雙抗)注射液用於慢性鼻竇炎伴鼻息肉患者的II期臨床試驗達到所有研究終點

康諾亞-B(02162.HK)：CM512(TSLP x IL-13雙抗)注射液用於慢性鼻竇炎伴鼻息肉患者的II期臨床試驗達到所有研究終點

200元/天！這項服務北京能報銷了

中国新闻周刊

康諾亞-B發布公告，公司的重點研發產品CM512已被國家藥品監督管理局藥品審評中心納入突破性治療品種名單，用於治療慢性鼻

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎國際,美股交易,港股交易,交易美股,股票信息,股價,美股行情,美股打新,港股打新,IPO打新,購買美股,全球投資","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/hant/stock/ENTL/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"ENTL","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ENTL\",,,,,undefined,":{"symbol":"ENTL","market":"US","secType":"STK","nameCN":"Leverage Shares 2X Long ENTG Daily ETF","latestPrice":6.0861,"timestamp":1789588800000,"preClose":6.0559,"halted":0,"volume":1809,"hourTrading":{"tag":"盘后","latestPrice":5.975,"preClose":6.0861,"latestTime":"19:30 EDT","volume":8,"amount":48.6888,"timestamp":1789601403435,"change":-0.1111,"changeRate":-0.018255,"amplitude":0},"delay":0,"changeRate":0.004986872306345842,"floatShares":25000,"shares":25000,"eps":0,"marketStatus":"已收盤","change":0.0302,"latestTime":"09-16 16:00:00 EDT","open":6.2,"high":6.294,"low":5.9,"amount":11138.3141985,"amplitude":0.065061,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1789632000000},"marketStatusCode":5,"adr":0,"adrRate":0,"listingDate":1422507600000,"exchange":"CBOE","adjPreClose":6.0559,"nav":6.07,"aum":151750,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":6.17,"preClose":6.0559,"latestTime":"08:26 EDT","volume":12,"amount":74.19,"timestamp":1789561619307,"change":0.1141,"changeRate":0.018841,"amplitude":0.008256},"postHourTrading":{"tag":"盘后","latestPrice":5.975,"preClose":6.0861,"latestTime":"19:30 EDT","volume":8,"amount":48.6888,"timestamp":1789601403435,"change":-0.1111,"changeRate":-0.018255,"amplitude":0},"volumeRatio":0.902424},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ENTL\",,,,,undefined,":{"symbol":"ENTL","floatShares":25000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.902424,"shares":25000,"dividePrice":0,"high":6.294,"amplitude":0.065061,"preClose":6.0559,"low":5.9,"week52Low":4.6027,"pbRate":"--","week52High":14.5091,"institutionHeld":0,"latestPrice":6.0861,"eps":0,"divideRate":0,"volume":1809,"delay":0,"ttmEps":0,"open":6.2,"prevYearClose":12.45,"prevWeekClose":7.1498,"prevMonthClose":6.76,"prevQuarterClose":14,"fiveDayClose":7.4132,"twentyDayClose":8.48},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ENTL\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ENTL\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ENTL\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ENTL\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2664383252","title":"更多創新藥有望納入醫保報銷","url":"https://stock-news.laohu8.com/highlight/detail?id=2664383252","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664383252?lang=zh_tw&edition=fundamental","pubTime":"2026-09-04 10:20","pubTimestamp":1788488426,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4588","ENTL","HART","IBBQ","IHI","LNGR","MEDX","06978","PSCH","159992","BK1161","BK1574","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660484381","title":"創新生物製劑落地中國！雙適應症惠及重度哮喘與鼻息肉患者","url":"https://stock-news.laohu8.com/highlight/detail?id=2660484381","media":"上观新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660484381?lang=zh_tw&edition=fundamental","pubTime":"2026-08-17 18:40","pubTimestamp":1786963204,"startTime":"0","endTime":"0","summary":"今天，阿斯利康宣布，泰适卓?（英文商品名：Tezspire?，通用名：特泽利尤单抗注射液）在中国正式获批上市。依托两项关键III期临床研究的积极成果，该药物在国内斩获双重适应症，可用于成人及12岁以上青少年重度哮喘的维持治疗，同时能够联合鼻用糖皮质激素，治疗经系统性糖皮质激素、手术治疗后仍无法有效控制病情的慢性鼻窦炎伴鼻息肉成人患者。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608173843332125.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608173843332125.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["TSDD","TSII","TSLR","TSL","TESL","TSLI","TSLG","TLA","CRSH","TSLL","09766","07366","TSLQ","TSLW","TSLZ","09366","TSLT","TEST","07766","TSLO","TSYY","ENTL","TSLS","TSLP","TSLY","ELOL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660334481","title":"泰適卓®雙適應症在華上市，為重度哮喘、慢性鼻竇炎伴鼻息肉患者提供生物製劑創新治療選擇","url":"https://stock-news.laohu8.com/highlight/detail?id=2660334481","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660334481?lang=zh_tw&edition=fundamental","pubTime":"2026-08-17 16:21","pubTimestamp":1786954860,"startTime":"0","endTime":"0","summary":"特泽利尤单抗的上市，为慢性鼻窦炎伴鼻息肉患者带来了新的治疗选择，有望帮助他们实现长期疾病控制，改善生活质量。携双适应症在华上市，特泽利尤单抗有望充分释放上游炎症通路靶点的临床价值，进一步完善我们在哮喘领域从轻中度到重度的全病程疾病管理布局，加速哮喘治疗迈向'临床治愈'愿景，同时满足广大慢性鼻窦炎伴鼻息肉患者的未尽之需。其中，高达10%的哮喘患者为重度哮喘22,23。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"http://wwwold.prnasia.com/story/archive/5027377_ZH27377_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/5027377_ZH27377_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK4585","LU0128525929.USD","LU2236285917.USD","LU2468319806.SGD","BK4007","LU2237443978.SGD","LU0320765992.SGD","AZNH","LU1267930573.SGD","LU2237443382.USD","LU2237443622.USD","ENTL","LU2417539215.USD","LU0029864427.USD","LU2089984988.USD","IPOS","LU2456880835.USD","IE00B3T34201.USD","LU2237443895.HKD","LU1829250122.USD","BK4568","LU2237443465.HKD","LU0310800379.SGD","LU2237443549.SGD","BK4588","LU0432979614.USD","LU0708994859.HKD","LU0109394709.USD","AZN","LU0889565916.HKD","LU2462157665.USD","LU0289739699.SGD","LU0058720904.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658605178","title":"康諾亞-B(02162)：CM512(TSLP x IL-13雙抗)注射液用於慢性鼻竇炎伴鼻息肉患者的II期臨床試驗達到所有研究終點","url":"https://stock-news.laohu8.com/highlight/detail?id=2658605178","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658605178?lang=zh_tw&edition=fundamental","pubTime":"2026-08-10 08:09","pubTimestamp":1786320562,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康诺亚-B 发布公告，公司自主研发的1类新药CM512注射液治疗慢性鼻窦炎伴鼻息肉的II期临床研究已完成数据揭盲及初步统计分析。结果显示：1、CM512达到了全部研究终点，各剂量组疗效表现相当。CM512快速起效，给药第4周即可快速缩小鼻息肉同时显著改善鼻塞，并促进嗅觉功能恢复。基于此II期结果，公司正在快速启动CM512注射液治疗CRSwNP的临床III期研究，并明确300mg，半年给药一次为用药方案。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1477751.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02162","BK1574","BMED","PSYK","IBBQ","BK1587","BK1161","MDTX","BK1583","IBBJ","ENTL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658605122","title":"康諾亞-B(02162.HK)：CM512(TSLP x IL-13雙抗)注射液用於慢性鼻竇炎伴鼻息肉患者的II期臨床試驗達到所有研究終點","url":"https://stock-news.laohu8.com/highlight/detail?id=2658605122","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658605122?lang=zh_tw&edition=fundamental","pubTime":"2026-08-10 08:09","pubTimestamp":1786320562,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IBBQ","PSYK","BMED","IBBJ","MDTX","ENTL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654383058","title":"200元/天！這項服務北京能報銷了","url":"https://stock-news.laohu8.com/highlight/detail?id=2654383058","media":"中国新闻周刊","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654383058?lang=zh_tw&edition=fundamental","pubTime":"2026-07-25 07:00","pubTimestamp":1784934000,"startTime":"0","endTime":"0","summary":"近期，北京市医保局、北京市人力资源和社会保障局发布通知，7月11日起，北京市正式执行独立收费项目“安宁疗护费”，将多项人文关怀项目囊括其中，并纳入甲类医保报销。依据前述通知，本次新增的“安宁疗护费”，涵盖患者病情评估、诊查、分级护理、心理及精神疏导、情绪安抚等所需的人力资源和基本物质资源消耗，标准为200元/天，这项费用将由政府承担。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/wm/2026-07-25/doc-iniiyimr4564959.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4585","ENTL","IHI","PSCH","BK4588","HART"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653715306","title":"康諾亞-B發布公告，公司的重點研發產品CM512已被國家藥品監督管理局藥品審評中心納入突破性治療品種名單，用於治療慢性鼻","url":"https://stock-news.laohu8.com/highlight/detail?id=2653715306","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653715306?lang=zh_tw&edition=fundamental","pubTime":"2026-07-23 12:27","pubTimestamp":1784780872,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["ENTL"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":7,"code":"91000000","status":"200"}]}}